ZS Pharma, Inc. (NASDAQ:ZSPH) shares moved down -4.22% in last trading session and ended the day at $62.87. ZSPH has a return on assets of -47.30%. ZS Pharma, Inc. (NASDAQ:ZSPH) quarterly performance is 24.15%.
ZS Pharma is a publicly-traded (ZSPH), biopharmaceutical company with offices in Redwood City, California and Coppell, Texas. ZS Pharma’s lead therapeutic candidate, ZS-9 (sodium zirconium cyclosilicate), is an investigational treatment for hyperkalemia that has been submitted to the FDA for potential approval for the treatment of hyperkalemia.
On 10 September, ZS Pharma, Inc. (NASDAQ:ZSPH), confirmed that it has participated in preliminary discussions with Actelion Ltd. (ALIOF) regarding a potential strategic transaction. ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so. These discussions may or may not lead to any transaction. ZS Pharma does not intend to comment further on market speculation or disclose any developments unless and until it otherwise deems further disclosure is appropriate or required.
Coffee Holding Company, Inc. (NASDAQ:JVA) ended the last trading day at $3.90. Company weekly volatility is calculated as 4.44% and price to cash ratio as 7.36. Coffee Holding Company, Inc. (NASDAQ:JVA) showed a weekly performance of -8.67%.
Coffee Holding Co., Inc. (NASDAQ: JVA) is a leading integrated wholesale coffee dealer and roaster, and one of the few coffee companies that offers a broad array of coffee products across the entire spectrum of consumer tastes, preferences and price points. A family-operated business for three generations, Coffee Holding has remained profitable through varying cycles of the coffee industry and economy.
Coffee Holding Company, Inc. (NASDAQ:JVA) reported Net income in the fiscal third quarter was approximately $0.1 million, or $0.02 per diluted share, compared to net income of approximately $0.8 million, or $0.11 per diluted share, in the year-ago quarter. Without the impact of hedging activities for the three months ended July 31, 2014 and 2015, our basic earnings per share would have been $0.08 for the 2014 period compared to approximately $0.05 per share for the 2015 period.
On 28 September, Flextronics International Ltd. (NASDAQ:FLEX) shares moved down -1.44% and was closed at $10.27. FLEX EPS growth in last 5 year was 102.40%. Flextronics International Ltd. (NASDAQ:FLEX) year to date (YTD) performance is -8.14%.
Flextronics International Ltd. (NASDAQ:FLEX) announced that it participated in the 2015 Citi Industrials Conference on 17 September, 2015.
Flextronics International, Ltd. (Reg. No. 199002645H) is a leading sketch-to-scale™ solutions company that designs and builds intelligent products for a connected world. With more than 200,000 professionals across 30 countries and a promise to help make the world Live smarter™, the company provides innovative design, engineering, manufacturing, real-time supply chain insight and logistics services to companies of all sizes in various industries and end-markets.
AbbVie Inc. (NYSE:ABBV) shares moved down -5.81% in last trading session and ended the day at $52.50. ABBV Gross Margin is 80.70% and its has a return on assets of 6.10%. AbbVie Inc. (NYSE:ABBV) quarterly performance is -21.85%.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
On 16 September, AbbVie Inc. (NYSE:ABBV) announced the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy compared to placebo. The trial was conducted in women with heavy menstrual bleeding (HMB) associated with uterine fibroids. Preliminary results showed that all of the elagolix treatment arms, with and without add-back therapy, reduced heavy menstrual bleeding as compared to placebo Uterine fibroids (also called leiomyomas or myomas) are noncancerous muscle tissue tumors of the uterus.
Intra-Cellular Therapies, Inc (NASDAQ:ITCI) caters to the Healthcare space. Its weekly performance is -27.16%. On the last day of trading company shares ended up at $37.04. Intra-Cellular Therapies, Inc (NASDAQ:ITCI) distance from 50-day simple moving average (SMA50) is 15.91%.
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is developing its lead drug candidate, ITI-007, which is in Phase III clinical development as a treatment for schizophrenia. ITI-007 Program includes ITI-007-005, which is in Phase II clinical trial, for the treatment in patients with an acutely exacerbated episode of schizophrenia, and ITI-007-200, which is in Phase I/II clinical trial, designed to evaluate the safety, tolerability and pharmacokinetics of low doses of ITI-007 in healthy geriatric subjects and in patients with dementia, including Alzheimer’s disease.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), announced positive results from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with schizophrenia. In this trial, once-daily ITI-007 60 mg met the primary endpoint and demonstrated antipsychotic efficacy with statistically significant superiority over placebo at Week 4 (study endpoint) as measured by the change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score (p=0.022). Moreover, ITI-007 60 mg showed significant antipsychotic efficacy as early as week 1, which was maintained at every time point throughout the entire study.
Leave a Reply